Back to top

Analyst Blog

Royalty Pharma, a private entity, recently announced its intention to acquire Elan Corporation, plc . Royalty Pharma intends to acquire Elan at $11 for every share of Elan and its American Depository Shares (ADS).

Royalty Pharma’s offer of $11 per share represents a premium of 12.6% to the Current Enterprise Value of Elan based on the closing share price of Elan on Feb 15, 2013. The offer also represents a 6.3% premium to Elan’s stock price as of the closing price on Feb 15, 2013.

Moreover, Royalty Pharma’s offer price represents a 12.7% cash premium to the volume weighted average closing share price of the Elan stock on the New York Stock Exchange between Feb 6, 2013 and Feb 15, 2013.

Royalty Pharma’s offer comes close on the heels of the update provided by Elan on its future plans after it announced the restructuring of multiple sclerosis drug Tysabri. Notably, Biogen Idec (BIIB - Analyst Report) gained full strategic, commercial and operational control over Tysabri earlier this month. As per the agreement, Elan will be receiving an upfront payment of $3.25 billion from Biogen.

For the first year, Biogen will make royalty payment of 12% on the worldwide net sales of Tysabri (for all indications). After the first year, Elan will receive a royalty of 18% on up to $2 billion of global net sales of Tysabri and 25% thereafter on over $2 billion of global net sales of Tysabri. The transaction is expected to close shortly.

Elan stated that it will invest a portion of its net proceeds of $3.25 billion into multiple business assets. The company also has plans to refinance its outstanding debt. Moreover, the company announced that it will institute a share repurchase program by utilizing $1 billion of the upfront proceeds post the restructuring of Tysabri.

The company recently announced that it will take into consideration any credible proposal from Royalty Pharma or any other party alongside these strategic transactions. We expect investor focus to remain on Royalty Pharma’s offer going forward.

Elan, a biotechnology company, currently carries a Zacks Rank #2 (Buy). Other well placed biotech stocks include Alkermes (ALKS - Analyst Report) and United Therapeutics Corporation (UTHR - Analyst Report). While Alkermes carries a Zacks #2 Rank, United Therapeutics carries a Zacks Rank #1(Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 26.54 +6.24%
SUPER MICRO… SMCI 25.98 +6.08%
TESLA MOTOR… TSLA 281.91 +4.53%
BAIDU ADS BIDU 222.49 +3.72%
RTI SURGICA… RTIX 5.50 +3.58%